BMY
The suit says “I’m buying”
Cwm LLC went shopping for Bristol Myers Squibb and came back with a much bigger bag: the firm added 422,041 shares, boosting its stake by 52.3% to 1.23 million shares worth about $66.27 million. That’s not exactly a meme-stock moon mission, but it is the kind of steady institutional nibbling that says, “We’re comfortable owning this one.”
Why you should care
Big holders don’t move shares with a dramatic headline the way an activist or a takeover would, but they can still matter. When a fund keeps adding to a large healthcare name like BMY, it can reinforce the idea that the market sees the stock as a cash-yielding, lower-beta defensive play rather than a fireworks factory.
The messy part: earnings weren’t perfect
Bristol Myers also just posted quarterly EPS of $1.26, missing estimates by $0.39, even though revenue of $12.50 billion beat expectations. The company kept its FY2026 guidance at 6.05 to 6.35 EPS, which is a little like saying, “Yes, we tripped on the stairs, but the house is still standing.”
The dividend crowd stays happy
BMY also declared a quarterly dividend of $0.63 per share, with an annualized payout of $2.52 and a yield around 4.4%. For income investors, that’s the carrot. For growth investors, the question is whether earnings can catch up to the still-solid revenue base.
Big picture: this filing doesn’t rewrite the Bristol Myers story, but it does show that at least one institutional buyer is still comfortable loading up on a big pharma name that’s offering yield, stability, and a few earnings potholes along the way.